ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ADAP Advocacy Releases Report on Patient Medical Debt





Findings from Quantitative Surveying of Patients in the United States

WASHINGTON, DC, April 23, 2025 /24-7PressRelease/ -- ADAP Advocacy today, as part of its 340B Project and in collaboration with the Community Access National Network (CANN), published a report on patient experiences with and perspectives on medical debt. The report – "Patient Medical Debt: Findings from Quantitative Surveying of Patients in the United States – April 2025" – found that nearly four out of five patients delayed or avoided medical care due to inability to pay (excluding the purchase of prescription drugs), and three-fourths of patients held medical debt.

Brandon M. Macsata, CEO of ADAP Advocacy, summarized: "The rising medical debt crisis in the United States is impacting patients across all chronic health conditions, including patients living with HIV. We are concerned that the big hospital systems are reaping the benefits of the 340B Drug Pricing Program, affording them lucrative drug rebates that are supposed to be used to expand access to affordable healthcare services, but not using those dollars as intended by the law. Studies have shown nearly seventy-five percent of medical debt is actually debt owed to hospitals, or hospital debt."

ADAP Advocacy received 673 responses to the Patient Medical Debt Survey. The report's key findings include:

• When asked if they have ever delayed or avoided medical care (excluding the purchase of prescription drugs) due to their inability to pay, 77% of respondents (n=484) indicated that indicated "yes."
• Similarly, 71% (n=442) indicated that they have delayed or avoided purchasing prescription drugs because of their inability to afford associated out-of-pocket costs.
• When asked if they personally held medical debt, 74% of respondents (n=460) indicated they did.
• Those respondents holding medical debt indicated that their debt is largely held by hospitals (39%) and specialty care physicians (22%).
• 66% (n=304) indicated that their medical debt is currently in collections.
• 40% (n=182) indicated that medical debt had impacted their credit scores.
• 70% (n=324) indicated that medical debt impacted their health status.

The report included findings from a quantitative survey of patients in the United States. The report can be downloaded here: https://tinyurl.com/yc635dcz.

To learn more about ADAP Advocacy, 340B Drug Pricing Program, or patient medical debt, please email info@adapadvocacy.org.

About ADAP Advocacy: ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.76
+5.49 (2.48%)
AAPL  272.19
+0.35 (0.13%)
AMD  201.06
+2.95 (1.49%)
BAC  54.26
-0.29 (-0.53%)
GOOG  303.75
+5.69 (1.91%)
META  664.45
+14.95 (2.30%)
MSFT  483.98
+7.86 (1.65%)
NVDA  174.14
+3.20 (1.87%)
ORCL  180.03
+1.57 (0.88%)
TSLA  483.37
+16.11 (3.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.